The State of Diabetes Device Cybersecurity in 2019

DiabetesMine takes a look at new standards for medical device cybersecurity, and mitigating risks to diabetes devices in particular in 2019.
Source: Diabetes Mine - Category: Endocrinology Authors: Source Type: blogs

Related Links:

Conclusion. Patients with higher BMI had lower preoperative PROMIS PF scores and experienced similar improvement in PROMIS PF scores in the postoperative period. This study established that PROMIS PF may be utilized to evaluate the recovery of obese patients following MIS TLIF. Level of Evidence: 3
Source: Spine - Category: Orthopaedics Tags: OUTCOMES Source Type: research
Finding the'missing'people walking around with undiagnosed type 2 diabetes, estimated at around 1 in 70 of the population, will require screening, but the question is how, say experts.Medscape News UK
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
TYPE 1 and type 2 diabetes are two well established conditions that affect a person ’s blood sugar control. But another type of diabetes, type 1.5 diabetes, is beginning to gain traction - what is it, and are you at risk?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Source: Digestive Diseases and Sciences - Category: Gastroenterology Source Type: research
Objective: To examine the association between hearing impairment and cognitive decline and to identify possible risk factors for presbycusis. Study Design: Cross-sectional survey in prospective cohort study. Setting: University hospital. Patients: A total of 322 participants aged>60 years, for whom all the below data were available, were enrolled in the study. There were 168 females and 154 males with a median age of 71 years (range: 60–89 yrs). Interventions: PROST (Project in Sado for Total Health), a medical database in Sado island Japan, was analyzed. Main Outcome Measures: Data on pure-tone a...
Source: Otology and Neurotology - Category: ENT & OMF Tags: SENSORINEURAL HEARING LOSS AND TINNITUS Source Type: research
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have a well-defined safety profile based on data obtained from numerous clinical trials, including cardiovascular outcomes trials (CVOTs) and postmarketing pharmacovigilance reporting. Adverse events including risk of genital mycotic infection and volume depletion-related events are consistent with the mechanism of action of this drug class. However, several emergent (albeit infrequent) serious safety issues have also been reported. In their respective CVOTs, the proportion of patients with reported diabetic ketoacidosis was similar in empagliflozin or canagliflozin compar...
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
The findings of recent clinical trials have shown that sodium-glucose co-transporter 2 (SGLT2) inhibitors produce effects beyond glucose lowering and have demonstrated beneficial cardiovascular effects that have been observed across a broad range of patients with type 2 diabetes mellitus. In particular, the cardiovascular benefit results largely from substantial and early effects of SGLT2 inhibition on cardiovascular death and hospitalization for heart failure. Recent cardiovascular outcomes trials (CVOTs) have also shown that relative risk reductions in cardiovascular outcomes were observed with SGLT2 inhibition both in p...
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Sodium-glucose co-transporter 2 (SGLT2) inhibitors immediately reduce the glomerular filtration rate (GFR) in patients with type 2 diabetes mellitus. When given chronically, they confer benefit by markedly slowing the rate at which chronic kidney disease progresses and are the first agents to do so since the advent of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). Salutary effects on the kidney were first demonstrated in cardiovascular outcomes trials and have now emerged from trials enriched in subjects with type 2 diabetes mellitus and chronic kidney disease.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Heart failure is a common complication among patients with type 2 diabetes mellitus and is associated with significantly increased risks of subsequent morbidity and mortality. Until recently, therapies and strategies were lacking to attenuate this excess risk of heart failure in this population. Sodium-glucose co-transporter 2 (SGLT2) inhibitors represent a unique class of glucose-lowering therapies that have multisystem health benefits. Three large cardiovascular outcomes trials have demonstrated consistent reductions in heart failure events among patients with type 2 diabetes mellitus with, or at risk for, atheroscleroti...
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Type 2 diabetes mellitus has long been recognized as a major risk factor for adverse atherosclerotic cardiovascular disease events; however, recent data indicate that heart failure is now emerging as the most common and morbid cardiovascular complication of type 2 diabetes mellitus. When heart failure develops in patients with type 2 diabetes, prognosis is ominous, highlighting the need for glucose-lowering therapies that can prevent heart failure, improve outcomes, or both. Prior to 2008, there was a paucity of randomized controlled trials evaluating long-term cardiovascular outcomes with glucose-lowering therapies.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
More News: Diabetes | Endocrinology | Medical Devices